Royal Bank of Canada Acquires 27,497 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Royal Bank of Canada grew its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 10.5% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 288,937 shares of the biopharmaceutical company's stock after buying an additional 27,497 shares during the period. Royal Bank of Canada owned 0.26% of Regeneron Pharmaceuticals worth $205,820,000 as of its most recent SEC filing.

A number of other hedge funds have also recently modified their holdings of the business. Capital International Investors increased its position in shares of Regeneron Pharmaceuticals by 41.6% during the 4th quarter. Capital International Investors now owns 4,736,929 shares of the biopharmaceutical company's stock valued at $3,373,859,000 after purchasing an additional 1,390,534 shares during the last quarter. Geode Capital Management LLC lifted its position in Regeneron Pharmaceuticals by 6.8% in the fourth quarter. Geode Capital Management LLC now owns 2,427,630 shares of the biopharmaceutical company's stock worth $1,726,940,000 after buying an additional 155,369 shares during the last quarter. Dodge & Cox lifted its position in shares of Regeneron Pharmaceuticals by 0.4% during the fourth quarter. Dodge & Cox now owns 2,321,316 shares of the biopharmaceutical company's stock worth $1,653,543,000 after purchasing an additional 9,381 shares during the last quarter. Price T Rowe Associates Inc. MD lifted its position in shares of Regeneron Pharmaceuticals by 63.5% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 2,085,447 shares of the biopharmaceutical company's stock worth $1,485,527,000 after purchasing an additional 810,144 shares during the last quarter. Finally, Franklin Resources Inc. increased its stake in shares of Regeneron Pharmaceuticals by 7.9% during the fourth quarter. Franklin Resources Inc. now owns 2,045,210 shares of the biopharmaceutical company's stock valued at $1,456,864,000 after buying an additional 149,124 shares during the period. Institutional investors own 83.31% of the company's stock.

Regeneron Pharmaceuticals Stock Up 3.1%

NASDAQ:REGN traded up $18.25 during mid-day trading on Tuesday, reaching $614.79. The stock had a trading volume of 1,102,019 shares, compared to its average volume of 792,581. The business's 50 day moving average is $596.79 and its 200 day moving average is $679.72. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $520.50 and a fifty-two week high of $1,211.20. The stock has a market cap of $66.38 billion, a P/E ratio of 16.06, a PEG ratio of 2.34 and a beta of 0.43. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.73 and a quick ratio of 3.95.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last posted its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $8.22 earnings per share for the quarter, missing the consensus estimate of $8.83 by ($0.61). The business had revenue of $3.03 billion during the quarter, compared to the consensus estimate of $3.40 billion. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The firm's revenue was down 3.7% compared to the same quarter last year. During the same period in the prior year, the company posted $9.55 earnings per share. As a group, sell-side analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, June 6th. Stockholders of record on Tuesday, May 20th will be paid a $0.88 dividend. The ex-dividend date is Tuesday, May 20th. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.57%. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is presently 8.96%.

Wall Street Analysts Forecast Growth

Several equities analysts have issued reports on the company. The Goldman Sachs Group cut their target price on Regeneron Pharmaceuticals from $917.00 to $804.00 and set a "buy" rating on the stock in a research note on Wednesday, April 30th. Robert W. Baird reduced their price objective on shares of Regeneron Pharmaceuticals from $759.00 to $652.00 and set a "neutral" rating for the company in a research note on Friday, April 25th. Leerink Partners upgraded shares of Regeneron Pharmaceuticals from a "market perform" rating to an "outperform" rating and boosted their price objective for the stock from $762.00 to $834.00 in a research note on Wednesday, February 5th. StockNews.com lowered shares of Regeneron Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Thursday, May 1st. Finally, JPMorgan Chase & Co. reduced their price objective on shares of Regeneron Pharmaceuticals from $1,100.00 to $1,000.00 and set an "overweight" rating for the company in a research note on Monday, March 31st. One research analyst has rated the stock with a sell rating, four have issued a hold rating, nineteen have given a buy rating and three have given a strong buy rating to the company's stock. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average target price of $890.60.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.